Cargando...
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
Evolocumab is a PCSK9 inhibitor which is administered subcutaneously, and when added to statin therapy it has been shown to cause a significant incremental LDL-C reduction, leading to a reduction of cardiovascular risk. Evolocumab has a favorable side effect profile, and its self-administration at h...
Gardado en:
| Publicado en: | Patient Prefer Adherence |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6214408/ https://ncbi.nlm.nih.gov/pubmed/30464416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S149423 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|